



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

June 19 2025

M/s. BSE Ltd.
Scrip Code: **524816**

M/s. National Stock Exchange of India Ltd
Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Our letters dated October 19th, 2023 and April 9th, 2024

With reference to the above cited subject, please find enclosed the update for the U.S. Food and Drug Administration (FDA) inspection at our Pharma Division located in Kothur, Hyderabad, India, which was conducted from June 9th – June 19th, 2025.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, June 19th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced conclusion of US FDA Inspection at our Pharma Division located at Kothur, Hyderabad.

The U.S. Food and Drug Administration (FDA) had conducted an inspection at our Pharma Division located in Kothur, Hyderabad, India, which was conducted from June 9th – June 19th, 2025.

On conclusion of the inspection, the Company received 7 (Seven) observations in the Form-483. The Company is confident it will address the observations within the stipulated timeline. Company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter)

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in

Rajesh Chebiyam, EVP - CHS

rajesh.chebiyam@natcopharma.co.in